Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for ...
Bloom is off the rose
Real-time stock price for Russell Investments Income Essentials Class F-6 (FRC2042.CF), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns
Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...